The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has committed up to $10 million to its next funding round for the Edmond J. Safra Core Programs for PD Research to prioritize research toward transformative treatments and a cure for Parkinson’s disease (PD).
We invite qualified researchers to apply to the Edmond J. Safra Core Programs for PD Research:
Rapid Response Innovation Awards: This program supports high-risk, high-reward projects with little-to-no existing preliminary data, but with potential to significantly impact our understanding of PD and open the field up to new targets or pathways that may ultimately feed the early drug development pipeline for a treatment of PD.
Target Validation: The Target Validation program supports work seeking to determine if manipulating a novel biological target has impact in a PD-relevant pre-clinical model – an essential early step to the development of potentially promising therapies.
Therapeutic Pipeline Program: Investigators working at either pre-clinical or clinical stages of drug and therapeutic development may apply to this program. Proposals must focus on a treatment strategy with clear potential for PD and have a well-defined plan for moving toward clinical utility for patients.
To learn more about how to apply, visit www.michaeljfox.org/research/apply-for-grant.html. MJFF will host an informational conference call to clarify and explain the goals of this funding initiative and answer applicant questions on Wednesday, Sept. 18, 2013, at 12pm US ET. To receive call-in details, RSVP via email to email@example.com.
Target Validation and Therapeutic Pipeline Program initial applications are due October 30. Rapid Response Innovation Awards proposals are accepted on a rolling basis with funding decisions made within six weeks of submission.
For a complete list of MJFF funding opportunities, visit https://www.michaeljfox.org/research/apply-for-grant.html.